<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00280592</url>
  </required_header>
  <id_info>
    <org_study_id>AFSSAPS 051016</org_study_id>
    <secondary_id>PHRC/04-03</secondary_id>
    <secondary_id>CIC0203/039</secondary_id>
    <nct_id>NCT00280592</nct_id>
  </id_info>
  <brief_title>Cranberry for Prevention of Urinary Tract Infections in Multiple Sclerosis Patients</brief_title>
  <acronym>CANNEBERGE</acronym>
  <official_title>Prospective, Randomized, Double-blind, Placebo-controlled Study on Parallel Groups Evaluating the Efficacy and Safety of Cranberry (Vaccinium Macrocarpon) in Prevention of Urinary Tract Infections in Multiple Sclerosis Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pierre Fabre Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bladder dysfunction occurs at some time in most patients with multiple sclerosis and these
      patients are prone to have recurrent urinary tract infections. Cranberry has been
      traditionally used for the treatment and prophylaxis of urinary tract infections but there is
      no reliable randomized controlled trial demonstrating evidence of cranberry's utility in this
      disease. The aim of our study is to assess the efficacy and safety of cranberry in the
      prophylaxis of urinary tract infections in patients with multiple sclerosis with a
      prospective randomized, double-blind and placebo-controlled clinical trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bladder dysfunction occurs at some time in 70 to 90% of patients with multiple sclerosis and
      these patients are prone to have recurrent urinary tract infections (UTI), leading to an
      important morbidity. Cranberry has been traditionally used for the treatment and prevention
      of UTI and research suggests that its mechanism of action is preventing bacterial adherence
      to host cell surface membrane.

      However, systematic reviews show the small sample sizes and the poor quality of available
      trials, determining that there is no reliable evidence of effectiveness of cranberry in UTI
      prophylaxis. Therefore, to assess whether cranberry is effective in reducing UTI in patients
      with multiple sclerosis, we have designed a randomized, double-blind, placebo-controlled
      trial. Efficacy will be evaluated on the time to onset of a UTI in the first year of
      treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to onset of a first UTI within one year of treatment.</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with at least one UTI during the one-year treatment</measure>
    <time_frame>Determined at M3, M6, M9 and M12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of UTI</measure>
    <time_frame>Determined at M3, M6, M9 and M12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score on Qualiveen® scale</measure>
    <time_frame>Determined at M3, M6, M9 and M12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatology of urinary disorders</measure>
    <time_frame>Determined at M3, M6, M9 and M12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EDSS score</measure>
    <time_frame>Determined at M3, M6, M9 and M12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of multiple sclerosis attacks</measure>
    <time_frame>Determined at M3, M6, M9 and M12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibiotics consumption</measure>
    <time_frame>Determined at M3, M6, M9 and M12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of cranberry</measure>
    <time_frame>Determined at M3, M6, M9 and M12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' observance to treatment</measure>
    <time_frame>Determined at M3, M6, M9 and M12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">171</enrollment>
  <condition>Multiple Sclerosis</condition>
  <condition>Urinary Tract Infections</condition>
  <condition>Bladder Dysfunction</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cranberry</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cranberry</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cranberry</intervention_name>
    <description>Dry essence of cranberry presented as 18 mg of proanthocyanidines sachets of powdered cranberry. Cranberry juice is administered twice a day (in the morning and in the evening).</description>
    <arm_group_label>Cranberry</arm_group_label>
    <other_name>Vaccinium macrocarpon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo presented as sachets of powder. Placebo juice is administered twice a day (in the morning and in the evening).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults aged 18 to 70, with multiple sclerosis, neurologically stable for at least 3
             months

          -  With an EDSS score ≥ 3

          -  Symptomatic bladder dysfunction: frequency, urgency, dysuria, incontinence (at least
             one of these symptoms), needing intermittent catheterization or not

          -  Ambulatory at inclusion

          -  Able to undergo evaluation

          -  Informed written consent

        Non-inclusion Criteria:

          -  Regular consumption of cranberry within 3 months before inclusion

          -  Symptomatic urinary tract infection at inclusion

          -  Chronic renal failure (creatinin clearance &lt; 10ml/min)

          -  Patients with urinary permanent catheterization

          -  Patients with hyperuricemia and risk of uric acid lithiasis

          -  Patients with oral anticoagulant treatment (antivitamins K)

          -  Peptic ulcer

          -  Intolerance to cranberry and/or excipients

          -  Urinary tract infections antibioprophylaxis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Michel Reymann, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>CHU Rennes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe Gallien, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Rennes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Unité de Médecine Physique et Réadaptation - CHU Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Médecine Physique et Réadaptation - Hôpital Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Médecine Physique et Réadaptation - Hôpital Raymond Poincaré</name>
      <address>
        <city>Garches</city>
        <zip>92380</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultations maladies infectieuses et tropicales, Hôpital Raymond Poincaré</name>
      <address>
        <city>Garches</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Médecine Physique et Réadaptation - Groupe Hospitalier de l'institut Catholique de Lille - Hôpital Saint Philibert</name>
      <address>
        <city>Lomme</city>
        <zip>59160</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rééducation Neurologique et Explorations Périnéales - Hôpital Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Mutualiste de Rééducation et de Réadaptation Fonctionnelles de KERPAPE</name>
      <address>
        <city>Ploemeur</city>
        <zip>56275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Médecine Physique et Réadaptation - Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Médecine Physique et Réadaptation Notre Dame de Lourdes</name>
      <address>
        <city>Rennes</city>
        <zip>35043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de médecine physique et réadapation Hopital de Rangueil</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2006</study_first_submitted>
  <study_first_submitted_qc>January 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2006</study_first_posted>
  <last_update_submitted>May 18, 2012</last_update_submitted>
  <last_update_submitted_qc>May 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prophylaxis</keyword>
  <keyword>Cranberry</keyword>
  <keyword>Neurogenic bladder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

